Blood plasma is big business — especially along the U.S.–Mexico border. Every day, thousands of Mexican citizens cross ...

The ASX has spent most of 2025 swinging between optimism and anxiety, with inflation scares, rate hike speculation, and an AI ...

Looking for ASX ideas before Christmas? These two shares stand out for different reasons, offering growth and income ...

Australia’s long-term competitiveness depends on fostering innovation, investing in skills and supporting advanced ...

An announcement from CSL ( ($AU:CSL) ) is now available. CSL Limited has announced an update on its ongoing share buy-back program, revealing that ...

It was another brutal year as investors navigated the chaos of US President Donald Trump, the ever inflating artificial ...

Let's see why these shares could be destined to outperform in 2026 according to analysts. The post Buy Australian: ASX stocks ...

uniQure and CSL have become the first pharma companies to get regulatory approval for a gene therapy for haemophilia B anywhere in the world, after the FDA cleared their Hemgenix therapy for adults ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines committee ...

Plasma physics is the study of a state of matter comprising charged particles. Plasmas are usually created by heating a gas until the electrons become detached from their parent atom or molecule. This ...

The development of laser–plasma accelerators began in the early 1980s, inspired by the pioneering work of Tajima and Dawson 1. Key to their operation is the fact that unlike the superconducting ...

Australian fund managers faced a challenging year in 2025, as market volatility turned potential winners into losers, and ...